The Relationship Between Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Cardiovascular High-Risk: A Cross-Sectional Investigation

Yapeng Li,[1] Huiting Shi,[1] Cui Liang,[1] Qiaotao Xie,[2] Baocang Lei,[2] Haowei Hu,[3] Haoran Wang,[2] Pengcheng Li,[1]

[1]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

[2]Luohe Central Hospital, Luohe Medical College, Luohe, China

[3]Leicester International Institute, Dalian University of Technology, Dalian, China

Corresponding to: Pengcheng Li, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Alternate corresponding author: Haoran Wang, Luohe Central Hospital, Luohe Medical College, Luohe, China

Abstract

Aims

The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio reflects the balance between atherogenic and anti-atherogenic lipid fractions. The study aims to investigate the utility of the TG/HDL-C ratio in identifying high-risk groups for cardiovascular disease (CVD) within the general population.

Methods

The current study was a branch of the ChinaHEART cohort in middle China that involved a total of 6,593 community-dwelling adults. We examine the association between TG/HDL-C and CVD high-risk in a cross-sectional investigation.

Results

Results from restricted cubic spline and ROC analyses revealed a significant relationship between higher TG/HDL-C levels and increased odds of cardiovascular high-risk, with the ratio exhibiting good discriminatory power (AUC=0.819 in the fully adjusted model). Logistic

regression further supported this association, indicating a 1.21-fold rise in the odds of high-risk for each unit increase in TG/HDL-C.

Conclusions

The TG/HDL ratio demonstrates potential as a valuable clinical tool for CVD prevention. By incorporating the TG/HDL ratio into risk assessment models, healthcare professionals can enhance risk stratification and identify high-risk individuals who may benefit from targeted interventions.

Key words:

TG/HDL-C ratio; cardiovascular high-risk; cross-sectional study; public health.

Introduction

Cardiovascular diseases (CVD) continue to be a leading cause of mortality and morbidity worldwide, imposing a significant burden on healthcare systems and society as a whole. Early identification of individuals at high risk of developing CVD is crucial for implementing targeted prevention and management strategies.(2) Traditional risk factors such as hypertension, dyslipidemia, smoking, and diabetes have been

widely recognized, but there is a growing interest in exploring novel biomarkers that may enhance risk stratification in the general population.(3)

In recent years, the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio has emerged as a potential marker for cardiovascular risk assessment.(4–8) This ratio reflects the balance between atherogenic and anti-atherogenic lipid fractions. and has been proposed as a simple and cost-effective tool to identify individuals at increased risk of CVD. Some studies have found that this indicator is associated with morbidity and mortality from cardiovascular disease.(4,9) However, there is still a lack of relevant studies on whether this indicator can identify high-risk groups of cardiovascular disease in the general population.

Our study aims to address this gap in knowledge by conducting a cross-sectional observational study to evaluate the utility of the TG/HDL-C ratio in identifying high-risk individuals for cardiovascular diseases in the general population. By examining this novel biomarker in a large and diverse sample, we seek to elucidate its potential as a screening tool for early risk stratification and intervention. If we can effectively identify

69 individuals at high risk of cardiovascular disease in the general
70 population using this indicator, we can intervene at earlier stages of
71 cardiovascular disease, thereby maximizing the prevention of major
72 adverse cardiovascular events.

73 # Methods

74 **Study population and data collection**

75 The current study is a branch of the China Health Evaluation And risk
76 Reduction through nationwide Teamwork (ChinaHEART) in Luohe City,
77 involving 6,859 community-dwelling adults recruited from two township
78 hospitals in Luohe City between November 2, 2021 and February 20,
79 2022. The ChinaHEART cohort is a population cohort launched by the
80 China National Center for Cardiovascular Diseases (NCCD) initially
81 aiming at cardiovascular disease (CVD) risk screening and
82 management.(10) Study methods has been described previously.(11) The
83 study strictly adhered to ethical guidelines, with approval granted by the
84 Ethics Committee of Fuwai Hospital and the Ethics Committee of Luohe
85 Central Hospital. Participants received detailed information on the study's
86 purpose, significance, and risks before participant, in accordance with the

87 Declaration of Helsinki. Written informed consent was obtained from all
88 participants. The inclusion criteria for this study are as follows: (1) Age:
89 35-75 years (born between January 1, 1946, and December 31, 1986); (2)
90 Residing near the survey site for at least 6 months in the 12 months prior
91 to screening; (3) Voluntarily participating in this project and signing the
92 informed consent form. The exclusion criteria are as follows: (1) Survey
93 participants with missing data; (2) Survey participants who answered
94 "unclear" to questionnaire items; (3) Survey participants with fasting time
95 less than 8 hours before blood collection.

96 We utilized standardized questionnaires to collect data on socio-
97 demographic characteristics (e.g., age, gender), lifestyle factors (e.g.,
98 smoking, alcohol consumption), medical history (including hypertension,
99 diabetes, dyslipidemia, coronary heart disease, myocardial infarction,
100 stroke), and medication usage (such as antihypertensive, hypoglycemic,
101 and lipid-lowering drugs) of the study participants. Data were collected
102 through an information system provided by the ChinaHEART study and
103 was uploaded directly to the national study center in the Fuwai Hospital.
104 The anonymous data used in the current study was applied from the

105 national study center in the Fuwai Hospital after they performed data
106 washing. Cardiovascular disease (CVD) was defined as a diagnosis of
107 coronary heart disease, previous myocardial infarction, or stroke. Body
108 mass index (BMI) was calculated as body mass in kilograms divided by
109 the square of height in meters. Waist circumference was measured by
110 placing a measuring tape horizontally around the abdomen at the
111 midpoint between the anterior superior iliac crest and the lower edge of
112 the twelfth rib. Systolic blood pressure (SBP) and diastolic blood pressure
113 (DBP) were measured in a seated resting position at least twice, and the
114 average values were recorded. Lipid profiles were assessed using
115 fingertip blood samples.
116 According to the risk assessment prediction map in the Guidelines
117 for Cardiovascular Risk Assessment and Management issued by the
118 World Health Organization in 2008, the risk assessment of cardiovascular
119 disease was conducted.(12) If the screening subjects had 10 years of risk
120 of cardiovascular disease 20%, they were judged as high risk.

121 **Statistics**

122 The study population was categorized based on quartiles of the TG/HDL-
123 C ratio for basic characteristic description. Normality of continuous
124 variables was assessed using the Kolmogorov-Smirnov test, with mean ±
125 standard deviation for normally distributed data, and median (25%-75%
126 interval) for non-normally distributed data. Categorical variables were
127 described using percentages. Distribution differences in high
128 cardiovascular risk proportions across TG/HDL-C ratio quartile
129 populations were illustrated with a percentage stacking bar graph.
130 Continuous variable comparisons between groups involved t-tests or
131 analysis of variance for normally distributed data, and rank sum tests for
132 non-normally distributed data. Chi-square tests were conducted for
133 categorical variable comparisons. The association between the TG/HDL-
134 C ratio and cardiovascular high risk was examined using logistic
135 regression analysis, with two models utilized: one without confounder
136 adjustments for univariate analysis, and another adjusting for
137 confounding factors including gender, age, marital status, BMI, waist
138 circumference, fasting blood glucose, smoking history, alcohol

consumption history, diabetes, and systolic and diastolic blood pressure. Nonlinear associations between the TG/HDL-C ratio and cardiovascular risk were explored through restricted cubic spline analysis, utilizing key points at the 10th, 25th, 50th, 75th, and 90th percentiles of the TG/HDL-C ratio. The ability of the TG/HDL-C ratio to identify high cardiovascular risk was evaluated using receiver operating characteristic (ROC) curve analysis. While conducting the ROC curve analysis, we calculated the appropriate cutoff value, and this cutoff value was used to divide the participants into the high and low TG/HDL-C groups for further logistic regression analysis. Furthermore, we used net reclassification improvement (NRI) index to quantify the added value of TG/HDL-C for the discriminative performance.

Results

A total of 6,593 participants with sufficient data were included in the study, comprising 1,417 individuals categorized as cardiovascular high-risk and 5,176 individuals in the non-high-risk category. The study cohort was stratified into four segments based on the TG/HDL-C ratio, highlighting notable variations in demographic and clinical characteristics

157 such as age, gender, height, weight, BMI, waist circumference, smoking
158 habits, alcohol consumption, history of hypertension, diabetes, as well as
159 levels of glucose, lipids, and blood pressure (refer to Table 1). The
160 distribution of high-risk individuals across these quartiles was 16%, 15%,
161 18%, and 38% respectively (view Figure 1).

162 To explore the nonlinear relationship between the TG/HDL-C ratio
163 and cardiovascular high-risk, a restricted cubic spline analysis was
164 conducted. The analysis revealed a positive association between elevated
165 TG/HDL-C ratio levels and an increased likelihood of cardiovascular
166 high-risk (see Figure 2).

167 The TG/HDL-C ratio's discriminatory ability in identifying
168 individuals at cardiovascular high-risk was evaluated through ROC
169 analysis (refer to Figure 3). Initially, in model 1, the AUC for the
170 TG/HDL-C ratio alone was 0.562 (95% CI 0.544-0.580) for all
171 participants. However, upon incorporating all covariates into the analysis
172 in model 2, the AUC significantly increased to 0.819 (95% CI 0.805-
173 0.834), suggesting the enhanced effectiveness of combining the TG/HDL-
174 C ratio with traditional cardiovascular risk factors for high-risk

identification. Notably, the NRI index showed a significant improvement in discriminative performance, with a value of 0.107 ± 0.030 ($p = 0.016$). Moreover, the ROC analysis identified the optimal cutoff value for the TG/HDL-C ratio as 1.18, enabling the classification of participants into high and low TG/HDL-C ratio groups.

The logistic regression analysis results examining the relationship between the TG/HDL-C ratio and cardiovascular high-risk are detailed in Table 2. In Model 1, a 1 unit increase in the TG/HDL-C ratio was associated with a 1.40-fold increase in the odds of cardiovascular high-risk (95% CI 1.30-1.51, $p < 0.001$). Comparatively, the high TG/HDL-C ratio group exhibited 1.61 times higher odds of high-risk than the low TG/HDL-C ratio group (95% CI 1.43-1.81, $p < 0.001$), while the highest quartile of the TG/HDL-C ratio had 1.79 times higher odds compared to the lowest quartile (95% CI 1.52-2.10, $p < 0.001$). In Model 2, each 1 unit rise in the TG/HDL-C ratio was associated with a 1.21-fold increase in the odds of cardiovascular high-risk (95% CI 1.11-1.32, $p < 0.001$). Additionally, the high TG/HDL-C ratio group demonstrated 1.27 times higher odds of high-risk compared to the low TG/HDL-C ratio group

193 (95% CI 1.10-1.47, p = 0.001), with the highest quartile of the TG/HDL-
194 C ratio displaying 1.49 times higher odds than the lowest quartile (95%
195 CI 1.21-1.83, p < 0.001).

196 **Discussion**

197 Cardiovascular disease (CVD) remains a significant global health burden,
198 necessitating the identification of individuals at high risk for effective
199 prevention and intervention strategies. The TG/HDL-C ratio has emerged
200 as a potential marker for assessing cardiovascular risk in the general
201 population. It has been observed that the ratio of TG/HDL-C ratio not
202 only provides an approximation of insulin resistance but also assists in
203 identifying patients with an atherogenic lipoprotein profile.(13) The
204 typical lipoprotein phenotype in insulin-resistant/hyperinsulinemic
205 patients is typified by high plasma TG and low HDL cholesterol levels,
206 smaller and denser LDL particles, as well as an increased accumulation of
207 remnant lipoproteins after a meal. This lipoprotein phenotype is not only
208 associated with insulin resistance, but it is also linked with an elevated
209 risk of cardiovascular disease.(14) Although plasma TG and HDL
210 cholesterol levels are commonly tested, the same cannot be said for the

211 LDL particle diameter or postprandial remnant concentrations.

212 Nonetheless, a previous study observed a robust correlation between the

213 TG/HDL cholesterol ratio and the LDL peak diameter.(15) Moreover, it

214 is suggested that a TG/HDL cholesterol concentration ratio of 3.5 can

215 accurately predict the presence of the small dense LDL phenotype (LDL

216 phenotype B). Therefore, by assessing plasma TG and HDL cholesterol

217 levels and computing their ratio, it is possible to obtain understanding

218 into three out of the four modifications in lipoprotein metabolism that

219 enhance the risk of cardiovascular disease in insulin-resistant patients.

220 Numerous epidemiological studies have examined the relationship

221 between the TG/HDL ratio and CVD risk. Most of these studies have

222 reported a positive association between a higher TG/HDL ratio and

223 increased CVD risk. For instance, a prospective cohort study by Gaziano

224 et al. found the ratio of triglycerides to HDL was a strong predictor of

225 myocardial infarction;(16) Urbina et al. suggests the TG/HDL ratio may

226 be a useful marker for identifying young individuals at risk for

227 developing arterial stiffness, an early sign of CVD;(17) Li et al. found a

228 positive correlation between the TG/HDL-C ratio and carotid intima

229 thickness, a marker of early atherosclerosis, in adolescents with type 2
230 diabetes;(18) Du et al. found that the TG/HDL ratio is associated with
231 insulin resistance, a major risk factor for CVD, in a Chinese
232 population;(19) Ren et al. found that the TG/HDL ratio is positively
233 associated with insulin resistance in newly diagnosed type 2 diabetes
234 patients, indicating an increased risk of CVD;(20) Squillace et al. found
235 that a higher TG/HDL ratio is predictive of the development of diabetes,
236 a major risk factor for CVD;(21) Hong et al. found that a high TG/HDL
237 ratio is associated with an increased risk of cardiovascular events in
238 patients with diabetes and coronary artery disease.(22)
239 The TG/HDL ratio holds clinical significance as a potential marker
240 for CVD prevention. It provides valuable insights into the balance
241 between TG and HDL levels, representing the interplay between
242 dyslipidemia and atherosclerosis. A higher TG/HDL ratio reflects an
243 increased atherogenic lipid profile and has been associated with arterial
244 stiffness, carotid intima thickness, insulin resistance and diabetes, all of
245 which contribute to CVD development. By incorporating the TG/HDL

246 ratio into risk assessment models, clinicians can more accurately identify
247 individuals at high risk for CVD and implement targeted interventions.
248 Despite the clinical significance of the TG/HDL ratio, several
249 limitations must be acknowledged. First, the cut-off values for defining
250 high TG/HDL ratios vary across studies, leading to heterogeneity in
251 research findings. Standardization of these thresholds is necessary to
252 ensure consistency and comparability between studies. Additionally,
253 confounding factors, including age, sex, lifestyle factors, and
254 comorbidities, may influence the association between the TG/HDL ratio
255 and CVD risk. Although some studies have attempted to account for these
256 factors, further research is needed to elucidate their precise impact.
257 Moreover, variations in laboratory methods for lipid profile assessment
258 may introduce measurement errors and affect the accuracy of TG and
259 HDL cholesterol estimations.
260 In conclusion, the TG/HDL ratio demonstrates potential as a
261 valuable clinical tool for CVD prevention. Its ability to capture the
262 interplay between triglycerides and HDL cholesterol provides a
263 comprehensive assessment of the atherogenic lipid profile. By

incorporating the TG/HDL ratio into risk assessment models, healthcare professionals can enhance risk stratification and identify high-risk individuals who may benefit from targeted interventions. However, standardization of cut-off values, better control of confounding factors, and harmonization of laboratory methods are needed to further validate the clinical significance of the TG/HDL ratio. With these advancements, the TG/HDL ratio could significantly contribute to the prevention and control of cardiovascular disease.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author Pengcheng Li and Haoran Wang, upon reasonable request.

Declaration of Interest statement

The authors declared that there is no conflict of interest.

Author Contributions statement

Conceptualization and Methodology: Haoran Wang, Pengcheng Li; Formal analysis: Yapeng Li, Huiting Shi, Cui Liang, Baocang Lei, Haowei Hu; Data Curation: Cui Liang, Qiaotao Xie, Baocang Lei,

Haowei Hu, Haoran Wang, Pengcheng Li; Writing: Yapeng Li, Huiting Shi, Cui Liang, Pengcheng Li; Funding acquisition: Qiaotao Xie, Haoran Wang, Pengcheng Li.

Fundings

The study is supported by grants from the National Natural Science Foundation of China (81803318, 82304229), Henan Provincial Science and Technology Research Project (212102310813), Henan Educational Committee (22B320003), and Luohe ministry of science and technology (20210110). The funders have no role in the design and implementation of the current study.

Ethical statement

This study was conducted with approval from the Ethics Committee of Fuwai Hospital (2014–574) as the Central Ethic, and was approved by the Ethics Committee of Luohe Central Hospital as the local ethic. This study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants.

298 **References**

299 1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E,
300 Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP,
301 et al. Global Burden of Cardiovascular Diseases and Risk Factors,
302 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*
303 (2020) 76:2982–3021. doi: 10.1016/j.jacc.2020.11.010

304 2. Zhao D, Liu J, Xie W, Qi Y. Cardiovascular risk assessment: a
305 global perspective. *Nat Rev Cardiol* (2015) 12:301–311. doi:
306 10.1038/nrcardio.2015.28

307 3. Thupakula S, Nimmala SSR, Ravula H, Chekuri S, Padiya R.
308 Emerging biomarkers for the detection of cardiovascular diseases.
309 *Egypt Heart J* (2022) 74:77. doi: 10.1186/s43044-022-00317-2

310 4. Yang M, Rigdon J, Tsai SA. Association of triglyceride to HDL
311 cholesterol ratio with cardiometabolic outcomes. *J Investig Med Off*
312 *Publ Am Fed Clin Res* (2019) 67:663–668. doi: 10.1136/jim-2018-
313 000869

314 5. Kosmas CE, Rodriguez Polanco S, Bousvarou MD,
315 Papakonstantinou EJ, Peña Genao E, Guzman E, Kostara CE. The
316 Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C)
317 Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular
318 Disease. *Diagnostics* (2023) 13:929. doi:
319 10.3390/diagnostics13050929

320 6. Che B, Zhong C, Zhang R, Pu L, Zhao T, Zhang Y, Han L.
321 Triglyceride-glucose index and triglyceride to high-density
322 lipoprotein cholesterol ratio as potential cardiovascular disease risk
323 factors: an analysis of UK biobank data. *Cardiovasc Diabetol* (2023)
324 22:34. doi: 10.1186/s12933-023-01762-2

325 7. Chen C, Dai J-L. Triglyceride to high-density lipoprotein cholesterol
326 (HDL-C) ratio and arterial stiffness in Japanese population: a
327 secondary analysis based on a cross-sectional study. *Lipids Health*
328 *Dis* (2018) 17:130. doi: 10.1186/s12944-018-0776-7

329 8. Chen Y, Chang Z, Liu Y, Zhao Y, Fu J, Zhang Y, Liu Y, Fan Z.
330 Triglyceride to high-density lipoprotein cholesterol ratio and
331 cardiovascular events in the general population: A systematic review
332 and meta-analysis of cohort studies. *Nutr Metab Cardiovasc Dis*
333 *NMCD* (2022) 32:318–329. doi: 10.1016/j.numecd.2021.11.005

334 9. Chen Z, Chen G, Qin H, Cai Z, Huang J, Chen H, Wu W, Chen Z,
335 Wu S, Chen Y. Higher triglyceride to high-density lipoprotein
336 cholesterol ratio increases cardiovascular risk: 10-year prospective
337 study in a cohort of Chinese adults. *J Diabetes Investig* (2020)
338 11:475–481. doi: 10.1111/jdi.13118

339 10. Wang R, Yang Y, Lu J, Cui J, Xu W, Song L, Wu C, Zhang X, Dai
340 H, Zhong H, et al. Cohort Profile: ChinaHEART (Health Evaluation
341 And risk Reduction through nationwide Teamwork) Cohort. *Int J*
342 *Epidemiol* (2023) 52:e273–e282. doi: 10.1093/ije/dyad074

343 11. Lu J, Xuan S, Downing NS, Wu C, Li L, Krumholz HM, Jiang L.
344 Protocol for the China PEACE (Patient-centered Evaluative
345 Assessment of Cardiac Events) Million Persons Project pilot. *BMJ*
346 *Open* (2016) 6:e010200. doi: 10.1136/bmjopen-2015-010200

347 12. WHO CVD Risk Chart Working Group. World Health Organization
348 cardiovascular disease risk charts: revised models to estimate risk in
349 21 global regions. *Lancet Glob Health* (2019) 7:e1332–e1345. doi:
350 10.1016/S2214-109X(19)30318-3

351 13. Reaven GM. The insulin resistance syndrome. *Curr Atheroscler Rep*
352 (2003) 5:364–371. doi: 10.1007/s11883-003-0007-0

353 14. Lorenzatti AJ, Toth PP. New Perspectives on Atherogenic
354 Dyslipidaemia and Cardiovascular Disease. *Eur Cardiol* (2020)
355 15:1–9. doi: 10.15420/ecr.2019.06

356 15. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as
357 an atherogenic index: correlation with lipoprotein particle size and
358 esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).
359 *Clin Biochem* (2001) 34:583–588. doi: 10.1016/s0009-
360 9120(01)00263-6

361 16. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE.
362 Fasting triglycerides, high-density lipoprotein, and risk of myocardial
363 infarction. *Circulation* (1997) 96:2520–2525. doi:
364 10.1161/01.cir.96.8.2520

365 17. Urbina EM, Khoury PR, McCoy CE, Dolan LM, Daniels SR,
366 Kimball TR. Triglyceride to HDL-C ratio and increased arterial
367 stiffness in children, adolescents, and young adults. *Pediatrics* (2013)
368 131:e1082-1090. doi: 10.1542/peds.2012-1726

369 18. Li X, Deng Y-P, Yang M, Wu Y-W, Sun S-X, Sun J-Z. Triglyceride
370 to high-density lipoprotein cholesterol ratio and carotid intima-
371 medial thickness in Chinese adolescents with newly diagnosed type 2
372 diabetes mellitus. *Pediatr Diabetes* (2016) 17:87–92. doi:
373 10.1111/pedi.12250

374 19. Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X. Clinical usefulness
375 of lipid ratios, visceral adiposity indicators, and the triglycerides and
376 glucose index as risk markers of insulin resistance. *Cardiovasc*
377 *Diabetol* (2014) 13:146. doi: 10.1186/s12933-014-0146-3

378 20. Ren X, Chen ZA, Zheng S, Han T, Li Y, Liu W, Hu Y. Association
379 between Triglyceride to HDL-C Ratio (TG/HDL-C) and Insulin
380 Resistance in Chinese Patients with Newly Diagnosed Type 2
381 Diabetes Mellitus. *PloS One* (2016) 11:e0154345. doi:
382 10.1371/journal.pone.0154345

383 21. Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A,
384 Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, et al.
385 Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus
386 development during ART. *J Antimicrob Chemother* (2016) 71:2663–
387 2669. doi: 10.1093/jac/dkw185

388 22. Yang S-H, Du Y, Li X-L, Zhang Y, Li S, Xu R-X, Zhu C-G, Guo Y-
389 L, Wu N-Q, Qing P, et al. Triglyceride to High-Density Lipoprotein
390 Cholesterol Ratio and Cardiovascular Events in Diabetics With
391 Coronary Artery Disease. *Am J Med Sci* (2017) 354:117–124. doi:
392 10.1016/j.amjms.2017.03.032

Tables

Table 1. Clinical characteristics of the study population by quartiles of TG/HDL-C.

	Q1	Q2	Q3	Q4	p-value
Number	N=1,648	N=1,648	N=1,648	N=1,649	
Age (median (IQR))	59.00 (50.00-67.00)	58.00 (50.00-67.00)	58.00 (51.00-66.00)	58.00 (52.00-66.00)	0.78
Male (%)	617 (37%)	613 (37%)	599 (36%)	667 (40%)	0.081
BMI (median (IQR))	24.12 (22.14-26.32)	24.80 (22.70-26.83)	25.15 (23.16-27.44)	26.04 (24.01-28.36)	<0.001
Waist (median (IQR))	83.00 (77.00-89.95)	85.00 (79.00-91.00)	86.00 (80.50-93.00)	89.00 (82.00-95.00)	<0.001
SBP (median (IQR))	135.00 (123.25-148.50)	136.00 (124.50-149.50)	136.00 (125.50-149.50)	141.50 (129.50-152.00)	<0.001
DBP (median (IQR))	82.50 (76.00-89.50)	82.50 (76.00-89.50)	82.50 (76.00-90.00)	85.00 (77.00-92.50)	<0.001
Current smoke (%)	338 (21%)	325 (20%)	300 (18%)	358 (22%)	0.083
Drinking (%)	86(5%)	68(4%)	98(6%)	107(6%)	0.018
HTN (%)	335(20%)	338(21%)	367(22%)	467(28%)	<0.001
DM (%)	72(4%)	96(6%)	91(6%)	147(9%)	<0.001
CHD (%)	36(2%)	25(2%)	19(1%)	13(1%)	0.006
Stroke (%)	63(4%)	37(2%)	41(2%)	40(2%)	0.021
TC (median (IQR))	4.08 (3.47-4.65)	4.53 (4.03-5.11)	4.97 (4.36-5.43)	5.62 (4.98-6.39)	<0.001
HDL (median (IQR))	1.71 (1.49-1.97)	1.50 (1.33-1.69)	1.39 (1.23-1.52)	1.21 (1.09-1.37)	<0.001
TG (median (IQR))	1.21 (0.95-1.62)	1.41 (1.11-1.74)	1.58 (1.25-2.00)	1.94 (1.47-2.69)	<0.001
LDL (median (IQR))	1.96 (1.45-2.44)	2.48 (2.09-2.88)	2.71 (2.32-3.17)	3.35 (2.71-4.03)	<0.001
Glu (median (IQR))	5.40 (5.10-5.80)	5.40 (5.10-5.90)	5.40 (5.11-6.00)	5.70 (5.30-6.40)	<0.001
TG/HDL-C (median (IQR))	2.43 (2.20-2.59)	3.02 (2.88-3.15)	3.55 (3.41-3.72)	4.50 (4.17-4.97)	<0.001
CVD_highrisk (%)	257 (16%)	251 (15%)	290 (18%)	620 (38%)	<0.001

Data are presented as median (IQR) for continuous variables, and number (percentage) for categorical variables. HTN, hypertension; DM, diabetes mellitus; CHD, coronary heart disease; BMI, body mass index; TC, total cholesterol; TG, triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 2. Association between TG/HDL-C ratio and cardiovascular high-risk by logistic regression.

	Model 1		Model 2	
	OR (95% CI)	**p**	**OR (95% CI)**	**p**
All participants				
TG/HDL-C (per 1 unit)	1.40 (1.30-1.51)	<0.001	1.21 (1.11-1.32)	<0.001
TG/HDL-C (high vs low)	1.61 (1.43-1.81)	<0.001	1.27 (1.10-1.47)	0.001
TG/HDL-C (quartile)				
Q1	Ref		Ref	
Q2	0.90 (0.75-1.07)	0.214	1.04 (0.85-1.29)	0.68
Q3	0.84 (0.71-1.01)	0.06	0.95 (0.77-1.18)	0.634
Q4	1.79 (1.52-2.10)	<0.001	1.49 (1.21-1.83)	<0.001
Female				
TG/HDL-C (per 1 unit)	1.36 (1.24-1.50)	<0.001	1.14 (1.01-1.28)	0.028
TG/HDL-C (high vs low)	1.52 (1.30-1.77)	<0.001	1.16 (0.96-1.40)	0.114
TG/HDL-C (quartile)				
Q1	Ref		Ref	
Q2	0.94 (0.74-1.19)	0.6	0.97 (0.74-1.28)	0.838
Q3	0.91 (0.72-1.15)	0.447	1.00 (0.76-1.32)	0.998
Q4	1.78 (1.44--2.20)	<0.001	1.33 (1.02-1.74)	0.034
Male				
TG/HDL-C (per 1 unit)	1.50 (1.33-1.69)	<0.001	1.31 (1.14-1.52)	<0.001
TG/HDL-C (high vs low)	1.82 (1.51-2.19)	<0.001	1.45 (1.15-1.84)	<0.001
TG/HDL-C (quartile)				
Q1	Ref		Ref	
Q2	0.85 (0.66-1.11)	0.238	1.14 (0.84-1.57)	0.432
Q3	0.78 (0.59-1.03)	0.076	0.90 (0.64-1.27)	0.557
Q4	1.94 (1.51-2.49)	<0.001	1.67 (1.20-2.32)	0.002

Figure legends

Figure 1. Percentage stacked histogram to visually represent the distribution of cardiovascular high-risk individuals across quartiles of the TG/HDL-C ratio.

Figure 2. Restricted cubic spline to assess the non-liner relationship between TG/HDL-C ratio and cardiovascular high-risk.

Figure 3. ROC curve to illustrate the discriminatory power of TG/HDL-C for cardiovascular high-risk.



Fig 1



Figure 2. Restricted cubic spline to assess the non-liner relationship between TG/HDL-C ratio and cardiovascular high-risk.

Fig 2


1.00
0.75
0.50
0.25
0.00
Sensitivity
0.00
0.25
0.50
0.75
1.00
1-specificity
Model 1 ROC area: 0.5621
Model 2 ROC area: 0.8193
Reference

Fig 3